All articles tagged with #car t therapy
A patient with an autoimmune disease died after receiving an experimental CAR-T gene therapy from a Chinese biotech startup, the third fatality in China’s controversial and opaque trials, according to Endpoints News.
Boulevard Bio, co-founded by renowned autoimmune researcher Georg Schett, signals a shift toward antibody therapies and away from CAR-T, marking Schett’s first co-foundership as he continues to advise several biotech startups.
Sam Neill, the Jurassic Park star, died in Australia at age 78, with his longtime representative confirming the cause of death as pneumonia after he battled lymphoma in 2022 and underwent CAR-T therapy. The family had announced he was cancer-free prior to his passing, describing the death as sudden, and a private memorial is planned at his New Zealand farm as fans await updates amid accompanying rumors.
Sam Neill, the 78-year-old star of Jurassic Park, died from pneumonia after battling a rare blood cancer treated with CAR-T therapy; he had four projects completed in the past year and a private memorial will be held at his farm in New Zealand.
Sam Neill died July 13 in Sydney at age 78, with his representative saying the cause was pneumonia after a cancer battle that had left him in remission thanks to CAR-T therapy. The family emphasized his privacy and noted there have been inaccuracies in recent reports; a private memorial will be held in New Zealand.
Entrepreneur Bryan Johnson revealed he has autoimmune gastritis, a hard-to-diagnose autoimmune attack on stomach acid–producing cells that can cause iron deficiency, anemia, and increased cancer risk. Medical experts urge more biopsies for iron-deficient patients to catch the condition, while Johnson weighs treatment options including iron supplementation and experimental approaches like CAR-T therapy, underscoring that even intense health optimization can’t fully shield someone from disease.
Multiple myeloma, a brutal blood cancer, is increasingly treatable thanks to CAR-T immunotherapy, especially Carvykti, a BCMA-targeting one-time infusion that has produced durable remissions and in some cases cures. Developed in China and licensed to a Western company, Carvykti’s success—with CARTITUDE-1 showing a 76% response rate and five-year data indicating about 33% disease-free—highlights a shift in biotech leadership from the US to China, driven by faster early-stage trials and regulatory reforms. The US still dominates late-stage development, but China’s rapid trial ecosystem is accelerating the global pipeline, potentially enabling earlier, even first-line, use of such therapies and signaling a broad realignment in drug discovery and approval.
Sam Neill says he is cancer-free after chemotherapy stopped working, thanks to CAR-T cell therapy, and he’s advocating for government funding of the treatment in Australia with support from the Snowdome Foundation.
Sam Neill, the Emmy-nominated star of Jurassic Park, said he’d been living with a type of lymphoma for about five years after chemotherapy stopped working, but after receiving CAR-T-cell therapy he is now cancer-free, per 7NEWS.
Sam Neill says he is cancer-free after undergoing CAR-T-cell therapy following chemotherapy’s failure, marking a five-year battle with angioimmunoblastic T-cell lymphoma. A recent scan found no cancer, and he plans to return to acting while advocating for broader CAR-T access in Australia.
A 47-year-old German woman with refractory autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome was treated with CAR-T cell therapy to eradicate rogue B cells and reboot her immune system. After exhausting standard therapies, this radical approach led to dramatic improvement and is described by doctors as a landmark in immunotherapy.
A 47-year-old woman with three autoimmune diseases caused by B-cell antibodies—autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome—was treated with a single dose of engineered CAR-T cells after failing multiple therapies. Following targeted conditioning chemotherapy, her blood counts normalized within a month, and 14 months later she remains symptom-free and off all medications, suggesting CAR-T therapy could offer a one-off cure for some autoimmune conditions, though this is a single case and long-term safety and applicability need further study.
Washington University researchers used CAR-T cell therapy to reprogram brain immune cells to recognize and clear amyloid beta plaques in mice, reducing plaques and dampening neuroinflammation. This is the first application of CAR-T to a neurodegenerative disease, but it is early-stage and not yet ready for humans; scientists plan safety and dosing studies and will explore translation to other disorders, with potential relevance for veterans at risk of dementia.
U.S. researchers are testing CAR-T therapy—reprogramming a patient’s own T cells to attack overactive B cells implicated in MS—to see if it can reach the brain and slow progression. Early, small trials (including four MS patients at the Cleveland Clinic) show uncertain outcomes and potential risks like cytokine release syndrome and neurotoxicity, with experts cautioning that this approach is highly experimental and may not be more effective than existing MS drugs. Still, findings could improve understanding of MS and guide future therapies, even if not curative.
Researchers engineered astrocytes to express a CAR targeting amyloid beta, turning them into brain “super cleaners.” In mice, a single gene-therapy injection either prevented plaque formation when given early or reduced existing amyloid plaques by ~50%, signaling a potential new immunotherapy approach for Alzheimer's—though safety and human trials remain to be established.